Summit Therapeutics Notes That Data From The Phase III HARMONi-GI1 Trial Will Be Presented At The European Society For Medical Oncology Congress, October 23–27
Data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the
A big medical test of a new drug will show its results at a doctor conference. When companies share test results publicly, watch if doctors think the drug works well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.